Skip to main content
. 2022 Aug 25;37(2):871–880. doi: 10.1007/s00464-022-09459-5

Fig. 3.

Fig. 3

Comparisons of PFS (a) and OS (b) between ER-alone and ER + SR treatment in high-risk group with LVI( +) and/or VM( +)